Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2011

View Archived Issues

Phase II study assesses BAF-312 in relapsing-remitting MS

Imaging agent [123I]-BZM-055 assessed in nonhuman primates

Lostam BioPharmaceutical presents monoclonal antibodies against P. aeruginosa flagellin

Scientists in Sweden identify new biomarker for disease activity in MS

Natural plant-derived product inhibits proliferation of gastric cancer cells

Novel sterol O-acyltransferase 2 inhibitors synthesized in Japan

New HIV integrase inhibitors presented by Critical Outcome Technologies

Johnson & Johnson submits sNDA to FDA for Nucynta ER

Circadian Technologies clear to start clinical development of VGX-100

Actelion Pharmaceuticals discloses novel antibacterials

Sanofi presents new Met inhibitors

Galena Biopharma focuses on late-stage targeted cancer drug development

Piramal Life Sciences synthesizes new cytokine inhibitors

Takeda Pharmaceutical prepares novel histamine H3 receptor antagonists

TNF-Kinoid shows promise in phase IIa trial

CytRx reports further on phase Ib/II study of INNO-206

FDA approves Pacira Pharmaceuticals' Exparel

European orphan drug status for Celldex Therapeutics' rindopepimut

Takara Bio to develop gene therapy for non-Hodgkin's lymphoma

MorphoSys and Shionogi extend HuCAL research partnership

Phase II study of CK-2017357 advances

NVB-302 enters clinical testing

Infinity Pharmaceuticals begins two studies of IPI-145

FDA approves Xience Prime stent

Avanir Pharmaceuticals submits MAA for Nuedexta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...